12 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp02270 | Camel | KWKLFKKIGAVLKVL | Ceropin-Melittin hybrid | Cell swelling and rupture of the plasma membrane | MTT/MTS assay | B16-F10 | Skin cancer | LC50 : 1.75 µM |
| dbacp03600 | l3,10,13K7,8K4R2L9 | KLlRLLkkLlRLlLK | Diastereomeric peptide | Plasma membrane perturbation; Necrosis | XTT assay | B16-F10 | Skin cancer | LC50 : 2.5 µM |
| dbacp03602 | l3,4,8,10K5L7 | KlllKLKlKlLK | Diastereomeric peptide | Plasma membrane perturbation; Necrosis | XTT assay | B16-F10 | Skin cancer | LC50 : 100 µM |
| dbacp05094 | P7 | PLLQATLGGGS | Not found | Apoptosis inducing | WST-1 assay | B16-F10 | Skin cancer | IC50 : 1 µM |
| dbacp06404 | Tyroserleutide | YSL | Synthetic Peptide | Necrosis; Immune regulation | MTT/MTS assay | B16-F10 | Skin cancer | 49.4% Cytotoxic at 0.1 µg/ml |
| dbacp06405 | Tyroserleutide | YSL | Synthetic Peptide | Necrosis; Immune regulation | MTT/MTS assay | B16-F10 | Skin cancer | 51.2% Cytotoxic at 1 µg/ml |
| dbacp06406 | Tyroserleutide | YSL | Synthetic Peptide | Necrosis; Immune regulation | MTT/MTS assay | B16-F10 | Skin cancer | 53.0% Cytotoxic at 10 µg/ml |
| dbacp06407 | Tyroserleutide | YSL | Synthetic Peptide | Necrosis; Immune regulation | MTT/MTS assay | B16-F10 | Skin cancer | 61.2% Cytotoxic at 100 µg/ml |
| dbacp06735 | NKL-WT | KLKSKLMVVCNKIGLLKSLCRKFVKSH | Trematomus bernacchii | Apoptosis inducing | luciferase-based ATPlite assay | B16-F10 | Skin Cancer | ATP level = 0.753 ± 0.254 at 40 μM |
| dbacp06736 | NKL-MUT | KLKSKLMVVANKIGLLKSLARKFVKSH | Trematomus bernacchii | Apoptosis inducing | luciferase-based ATPlite assay | B16-F10 | Skin Cancer | ATP level = 0.023 ± 0.007 at 40 μM |
| dbacp07239 | RB4 | MADSERLSAPGCWAACTNFSRTRK | Derived from protein PLP2 | F-actin modulation induces necrotic death. | MTT assay | B16-F10-Nex 2 | Skin Cancer | EC50 = 0.263 ± 0.585 mol/L × 10-3 |
| dbacp07493 | Figainin 1 | FIGTLIPLALGALTKLFK | Boana raniceps | Membrane disruption, α-helix mediated | MTT assay | B16-F10 | Skin Cancer | IC50 = 10.5 µM |